Unfractionated Heparin: Clinical Management Guide

Primary Recommendation

For adult patients requiring anticoagulation with unfractionated heparin (UFH), initiate therapy with a weight-based bolus of 80 IU/kg (maximum 5,000 units) followed by continuous infusion of 18 IU/kg/hour (maximum 1,000 units/hour), targeting an aPTT ratio of 1.5-2.5 times control or anti-Xa level of 0.30-0.70 IU/mL 1, 2.

Indications for UFH

UFH remains appropriate for specific clinical scenarios despite the availability of low-molecular-weight heparins 2:

Venous thromboembolism (DVT/PE) treatment and prophylaxis
Acute coronary syndromes (unstable angina, acute MI)
Atrial fibrillation with embolization
Cardiac and arterial surgery (including extracorporeal circulation)
Severe renal impairment (GFR <30 mL/min) where rapid reversibility is needed
High bleeding risk situations requiring immediate anticoagulation cessation capability
Perioperative bridging during warfarin interruption (therapeutic dose: target aPTT 1.5-2.0 times control) 3

Critical caveat: For most hospitalized patients with VTE without these specific circumstances, low-molecular-weight heparin or direct oral anticoagulants are preferred first-line agents due to superior efficacy, lower bleeding rates, and reduced heparin-induced thrombocytopenia risk 4.

Dosing Regimens

Therapeutic Anticoagulation

For VTE treatment 1, 2:

Bolus: 80 IU/kg IV (or 5,000 units)
Infusion: 18 IU/kg/hour (or 32,000 units/24 hours)
Adjust based on monitoring parameters

For acute coronary syndromes 5:

With fibrinolytic therapy: 60 IU/kg bolus (max 4,000 units), then 12 IU/kg/hour infusion (max 1,000 units/hour)
Without fibrinolytic therapy: 60-70 IU/kg bolus (max 5,000 units), then 12-15 IU/kg/hour infusion

Special populations 6:

Elderly (≥65 years) or obese (≥100 kg): Consider adjusted body weight dosing to achieve therapeutic levels faster (median 13.6 vs 20.9 hours with total body weight)

Prophylactic Dosing

VTE prophylaxis 1:

5,000 units subcutaneously every 8-12 hours
No monitoring required for prophylactic doses

Monitoring Parameters

Preferred Monitoring Approach

Anti-Xa assay is the preferred monitoring method over aPTT 7, 8:

Target range: 0.30-0.70 IU/mL (equivalent to 0.2-0.4 U/mL by protamine titration)
Less affected by pre-analytical variables and patient-specific factors
More standardized across laboratories
Particularly important in critically ill patients

Alternative: aPTT Monitoring

If anti-Xa unavailable 1, 9:

Target: aPTT ratio 1.5-2.5 times control (typically 50-70 seconds)
Critical limitation: Each institution must establish local therapeutic range due to reagent variability
Less reliable in critically ill patients, those with lupus anticoagulant, or elevated factor VIII

Monitoring Schedule

Baseline: aPTT or anti-Xa, CBC with platelet count, PT/INR
During therapy: Check aPTT or anti-Xa 6 hours after initiation or dose change 1
Platelet monitoring: Every 2-3 days to detect heparin-induced thrombocytopenia 2
Ongoing: Daily CBC, adjust infusion rate based on coagulation parameters

Pre-analytical Considerations 8

Use standard 3.2% buffered trisodium citrate tubes
Centrifuge within 1 hour of collection
Test within 10 minutes of centrifugation (1 hour acceptable)
Avoid CTAD tubes (unnecessary cost, uncertain benefit)

Dose Adjustment Protocol

Use weight-based nomograms for systematic dose adjustments 1, 8:

Example adjustment based on aPTT:

<1.2× control: Increase infusion by 3-4 IU/kg/hour, rebolus 80 IU/kg
1.2-1.5× control: Increase infusion by 2 IU/kg/hour
1.5-2.5× control: No change (therapeutic)
2.5-3.0× control: Decrease infusion by 2 IU/kg/hour
>3.0× control: Hold infusion 1 hour, decrease by 3 IU/kg/hour

Reversal Protocol

Protamine Sulfate Administration 2, 10

Dosing calculation:

1 mg protamine neutralizes approximately 100 units of heparin
Dose depends on time since last heparin administration (heparin half-life ~30 minutes)
Maximum rate: 50 mg over 10 minutes (risk of anaphylactoid reactions)

Time-based dosing:

Immediate (<30 min): 1 mg protamine per 100 units heparin given
30-60 minutes: 0.5-0.75 mg per 100 units
>60 minutes: 0.25-0.5 mg per 100 units

Monitoring reversal:

Check thrombin time or aPTT immediately and 1 hour post-protamine
Have resuscitation equipment available (anaphylaxis risk)

Critical Safety Considerations

Contraindications 2

Absolute: History of heparin-induced thrombocytopenia (HIT/HITT), known hypersensitivity to heparin or pork products
Relative: Active major bleeding, inability to perform appropriate coagulation monitoring

Heparin-Induced Thrombocytopenia 2

Monitor: Platelet count every 2-3 days during therapy
Suspect HIT if: Platelet count drops >50% from baseline or <150,000/μL
Action: Immediately discontinue heparin, switch to alternative anticoagulant (argatroban, bivalirudin)
Do not: Give platelet transfusions or restart any heparin product

Bleeding Management

Minor bleeding: Reduce infusion rate or temporarily hold
Major bleeding: Discontinue immediately, consider protamine reversal
Risk factors: Concurrent antiplatelet agents, recent surgery, renal/hepatic dysfunction, age >65 years

Practical Implementation

Avoid these common pitfalls:

Using empiric dosing instead of weight-based protocols (leads to longer time to therapeutic anticoagulation) 11
Relying solely on aPTT in critically ill patients (use anti-Xa when available) 7
Failing to establish local aPTT therapeutic ranges (reagent variability is substantial) 9
Delaying platelet monitoring (HIT can develop rapidly)
Using total body weight in elderly or obese patients (consider adjusted body weight) 6

For perioperative bridging 3: Stop UFH infusion 4-6 hours before surgery (short half-life allows rapid offset); resume 12-24 hours postoperatively if hemostasis adequate.

What are the appropriate indications, dosing regimens, monitoring parameters, and reversal protocol for unfractionated heparin in adult patients requiring anticoagulation?

Have a follow-up question?